ArticleOncology letters2018
Clinicopathological analysis of epithelioid inflammatory myofibroblastic sarcoma.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- Clinical management and long-term outcomes in pulmonary inflammatory myofibroblastic tumor: a 12-Year experience with 14 surgically treated adult patients at a single center.World journal of surgical oncology · 2025Article
- Inflammatory myofibroblastic tumor in the liver after bone marrow transplantation: case report and literature review.Frontiers in medicine · 2025Article
- Thoracic epithelioid inflammatory myofibroblastic sarcoma: a rare and aggressive disease with case report and literature review.Discover oncology · 2024Article
- Rare giant epithelioid inflammatory myofibroblastic sarcoma of the abdominal cavity in a child: a case report and review of the literature.Frontiers in oncology · 2024Article
- Huge intermediate-grade myofibroblastic sarcoma in the retroperitoneum revealed byFrontiers in medicine · 2024Article
- Epithelioid inflammatory myofibroblastic sarcoma with exceptionally long response to lorlatinib-a case report.Therapeutic advances in medical oncology · 2024Article
- Managing Inflammatory Myofibroblastic Tumor of the Uterus: A Case Report and Comprehensive Review of Pathological and Therapeutic Approaches.The American journal of case reports · 2023Review
- Development and validation of a nomogram for predicting survival in patients with malignant myofibroblastic tumor.Cancer medicine · 2023Article
- Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion.Frontiers in oncology · 2023Article
- Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib.Frontiers in oncology · 2023Article
- Epithelioid inflammatory myofibroblastic sarcoma: a case report and brief literature review.Frontiers in oncology · 2023Article
- Epithelioid Inflammatory Myofibroblastic Sarcoma With Poor Response to Crizotinib: A Case Report.Clinical medicine insights. Case reports · 2023Article
- Inflammatory Myofibroblastic Tumour: State of the Art.Cancers · 2022Review
- Pericardial Epithelioid Inflammatory Myofibroblastic Sarcoma: An Atypical Presentation.Cureus · 2022Article
- Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature.Brain tumor pathology · 2022Review
- Epithelioid Inflammatory Myofibroblastic Sarcoma Presenting as Gastrointestinal Bleed: Case Report and Literature Review.JPGN reports · 2021Review
- Epithelioid inflammatory myofibroblastic sarcoma: the youngest case reported.Autopsy & case reports · 2021Article
- Clinical characteristics and outcomes of 17 cases of inflammatory myofibroblastic tumor at a University Hospital in China.Oncology letters · 2021Article
- Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Epithelioid inflammatory myofibroblastic sarcoma of stomach: diagnostic pitfalls and clinical characteristics.International journal of clinical and experimental pathology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory myofibroblastic tumor (IMT) is a distinctive neoplasm composed of myofibroblastic and fibroblastic spindle cells, accompanied by the inflammatory infiltration of plasma cells, lymphocytes and/or eosinophils. Epithelioid inflammatory myofibroblastic sarcoma (EIMS), which primarily consists of cells with a round or epithelioid morphology, is associated with a poor prognosis and rapid development of local recurrence, and has been recognized to be a variant of IMT. Diagnosis of EIMS is difficult owing to its close resemblance to malignant mesothelioma, anaplastic large cell lymphoma, gastrointestinal stromal tumor and other malignant diseases. In the present study, a case of this rare tumor was evaluated in a 26-year-old male who was admitted to hospital after experiencing abdominal pain for ~18 days and abdominal distention for 1 week. The patient's tumor was examined by imaging, gross examination, histology, immunohistochemistry and fluorescence
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.